Summary
25.25 -0.39(-1.50%)10/04/2024
Bridgebio Pharma LLC (BBIO)
Bridgebio Pharma LLC (BBIO)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.46 | 1.10 | -17.66 | -1.98 | -10.32 | 5.10 | 29.93 | -8.37 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.25 | |
| Open | 25.81 | |
| High | 26.05 | |
| Low | 25.14 | |
| Volume | 1,149,282 | |
| Change | -0.38 | |
| Change % | -1.46 | |
| Avg Volume (20 Days) | 1,723,994 | |
| Volume/Avg Volume (20 Days) Ratio | 0.67 | |
| 52 Week Range | 21.68 - 44.32 | |
| Price vs 52 Week High | -43.04% | |
| Price vs 52 Week Low | 16.44% | |
| Range | -2.19 | |
| Gap Up/Down | 0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 4,603 | |
| EBIDTA | -239,619,008 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 81.20 | |
| Book Value | 3.9180 | |
| Earnings Per Share | -3.8850 | |
| EPS Estimate Current Quarter | -0.9000 | |
| EPS Estimate Next Quarter | -0.9200 | |
| EPS Estimate Current Year | -3.6900 | |
| EPS Estimate Next Year | -3.8100 | |
| Diluted EPS (TTM) | -3.8850 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -9.3975 | |
| Return on asset (TTM) | -0.4263 | |
| Return on equity (TTM) | -17.8967 | |
| Revenue TTM | 56,952,000 | |
| Revenue per share TTM | 0.4130 | |
| Quarterly Revenue Growth (YOY) | -0.7120 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 8,249,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 123.6828 | |
| Revenue Enterprise Value | 107.5645 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 147,184,992 | |
| Shares Float | 70,254,379 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.36 | |
| Institutions (%) | 96.08 | |
10/04 05:17 EST - fool.com
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
3 Top Stocks That Could Still Rocket Higher in 2024
Upcoming Food and Drug Administration decisions could push these stocks through the roof.
10/03 07:30 EST - globenewswire.com
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.
BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions
PALO ALTO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that outcomes data through 42 months from the ongoing long-term open-label extension of ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a featured science oral presentation at the American Heart Association (AHA) Scientific Sessions, taking place in Chicago, Illinois on November 16 – 18, 2024. In addition to the presentation, BridgeBio was selected to share three posters in moderated poster sessions on ATTR-CM.
09/30 13:17 EST - benzinga.com
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
On Friday, BridgeBio Pharma, Inc. BBIO presented a post-hoc analysis evaluating the effect of acoramidis on the composite endpoint of all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) events in its Phase 3 ATTRibute-CM study in ATTR-CM.
BridgeBio Pharma's Lead Candidate Cuts Mortality, Related Hospitalizations In Patients With Certain Type Of Heart Disease
On Friday, BridgeBio Pharma, Inc. BBIO presented a post-hoc analysis evaluating the effect of acoramidis on the composite endpoint of all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) events in its Phase 3 ATTRibute-CM study in ATTR-CM.
09/30 07:30 EST - globenewswire.com
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio believes there is an opportunity to pursue Accelerated Approval in the U.S. for BBP-418 in LGMD2I/R9 based on a potential biomarker surrogate endpoint of glycosylated alpha-dystroglycan (αDG) at time of the interim analysis - If successful, BBP-418 could be the first approved therapy for individuals living with LGMD2I/R9 in the U.S. - Enrollment completion announced on 10 th annual LGMD Awareness Day, a collaborative yearly effort on September 30 th to globally raise awareness of individuals living with LGMD PALO ALTO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced, on LGMD Awareness Day, the completion of enrollment of FORTIFY, the Company's Phase 3 registrational study of BBP-418 in individuals with LGMD2I/R9.
BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
- Study exceeded target enrollment, with an expected topline data readout from the interim analysis expected in 2025 - BridgeBio believes there is an opportunity to pursue Accelerated Approval in the U.S. for BBP-418 in LGMD2I/R9 based on a potential biomarker surrogate endpoint of glycosylated alpha-dystroglycan (αDG) at time of the interim analysis - If successful, BBP-418 could be the first approved therapy for individuals living with LGMD2I/R9 in the U.S. - Enrollment completion announced on 10 th annual LGMD Awareness Day, a collaborative yearly effort on September 30 th to globally raise awareness of individuals living with LGMD PALO ALTO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced, on LGMD Awareness Day, the completion of enrollment of FORTIFY, the Company's Phase 3 registrational study of BBP-418 in individuals with LGMD2I/R9.
09/27 18:00 EST - globenewswire.com
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
- Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo
09/18 11:40 EST - 247wallst.com
3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.
3 Best High-Growth Mid-Cap Stocks to Buy in September 2024
Investors are optimistic that small- and mid-cap stocks will rally this year after a tough 2023, as attention shifts from the AI-focused Magnificent Seven.
09/17 07:30 EST - globenewswire.com
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA's requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoint(s)
BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA
- Breakthrough Therapy Designation was granted based on preliminary clinical evidence from the PROPEL 2 clinical trial, meeting the FDA's requirement of potentially demonstrating substantial improvement in efficacy over available therapies on clinically significant endpoint(s)
09/10 17:09 EST - reuters.com
BridgeBio to stop development of therapy for genetic disorder
BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.
BridgeBio to stop development of therapy for genetic disorder
BridgeBio Pharma said on Tuesday it will stop development of its experimental therapy for a genetic disease that affects the adrenaline-producing gland.
09/10 16:45 EST - globenewswire.com
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
- Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients
BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
- Increase in endogenous cortisol production achieved in all patients in higher dose cohorts of BBP-631, a result seen for the first time ever in CAH patients
09/10 16:45 EST - globenewswire.com
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
- Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812 has potential to address the unmet needs of individuals with Canavan disease
BridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program
- Receipt of RMAT Designation is based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial, which showed functional improvements in all dosed patients indicating that BBP-812 has potential to address the unmet needs of individuals with Canavan disease
09/06 07:30 EST - globenewswire.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on September 4, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 123 new employees in restricted stock units for an aggregate of 359,926 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on September 4, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 123 new employees in restricted stock units for an aggregate of 359,926 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
08/31 08:00 EST - seekingalpha.com
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
BridgeBio's stock is underperforming this year despite the progress the company made in recent quarters. HELIOS-B trial of Alnylam's Amvuttra (vutrisiran) was keeping investors away from BridgeBio, but the data presentation this week should lift this overhang on the stock. Investor focus should turn to the potential FDA approval and launch of acoramidis for the treatment of ATTR CM, followed by three late-stage clinical readouts in 2025.
BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis
BridgeBio's stock is underperforming this year despite the progress the company made in recent quarters. HELIOS-B trial of Alnylam's Amvuttra (vutrisiran) was keeping investors away from BridgeBio, but the data presentation this week should lift this overhang on the stock. Investor focus should turn to the potential FDA approval and launch of acoramidis for the treatment of ATTR CM, followed by three late-stage clinical readouts in 2025.
08/30 10:50 EST - globenewswire.com
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the OLE (n=21) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18)
BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension
- In participants who switched from tafamidis and placebo in the ATTRibute-CM study to acoramidis in its open-label extension (OLE), there was a mean of 3.0mg/dL increase in serum transthyretin (TTR) at Month 1 of the OLE (n=21) and mean of 3.4mg/dL increase in serum TTR at Month 6 of the OLE (n=18)
08/29 07:30 EST - globenewswire.com
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2024, taking place in London, United Kingdom on August 30 – September 2, 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, taking place in Atlanta, Georgia on September 27 - 30, 2024.
BridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024
PALO ALTO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced today that additional data on clinical outcomes from ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be presented at the European Society of Cardiology (ESC) Congress 2024, taking place in London, United Kingdom on August 30 – September 2, 2024 and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, taking place in Atlanta, Georgia on September 27 - 30, 2024.
08/28 07:30 EST - globenewswire.com
BridgeBio Pharma to Participate in September Investor Events
PALO ALTO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of the management team will participate in the following upcoming investor conferences:
BridgeBio Pharma to Participate in September Investor Events
PALO ALTO, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of the management team will participate in the following upcoming investor conferences:
08/26 07:30 EST - globenewswire.com
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
- The TRACE-AI Network Study will deploy a scalable screening toolkit for ATTR-CM across large, diverse health system electronic health records (EHRs) aiming to identify individuals who have ATTR-CM earlier in their disease course and quantify the potential prevalence of undiagnosed ATTR-CM
BridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial Intelligence
- The TRACE-AI Network Study will deploy a scalable screening toolkit for ATTR-CM across large, diverse health system electronic health records (EHRs) aiming to identify individuals who have ATTR-CM earlier in their disease course and quantify the potential prevalence of undiagnosed ATTR-CM
08/22 15:15 EST - seekingalpha.com
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
The FDA accepted BridgeBio Pharma, Inc.'s NDA regulatory submission of Acoramidis for the treatment of patients with ATTR-CM and set a PDUFA date of November 29th of 2024. Partnership established with Bayer to commercialize Acoramidis for the treatment of patients with ATTR-CM in European territories; Regulatory approval for Europe expected in 2025. The transthyretin amyloidosis treatment market size is expected to reach $11.2 billion by 2032.
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
The FDA accepted BridgeBio Pharma, Inc.'s NDA regulatory submission of Acoramidis for the treatment of patients with ATTR-CM and set a PDUFA date of November 29th of 2024. Partnership established with Bayer to commercialize Acoramidis for the treatment of patients with ATTR-CM in European territories; Regulatory approval for Europe expected in 2025. The transthyretin amyloidosis treatment market size is expected to reach $11.2 billion by 2032.
08/19 07:30 EST - globenewswire.com
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED Therapeutics, the BridgeBio affiliate focused on developing treatment options for skeletal dysplasias, today announced the launch of the initial phase of MyAchonJourney, a new online resource to support individuals and families living with achondroplasia.
BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
PALO ALTO, Calif., Aug. 19, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, and QED Therapeutics, the BridgeBio affiliate focused on developing treatment options for skeletal dysplasias, today announced the launch of the initial phase of MyAchonJourney, a new online resource to support individuals and families living with achondroplasia.
08/17 02:57 EST - seekingalpha.com
BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
BridgeBio Pharma focuses on developing therapies for genetic diseases with a threefold approach to managing costs and timelines effectively. The company employs a threefold R&D strategy: streamlined discovery, decentralized teams, and efficient development processes. BBIO's pipeline includes late-stage drug candidates like Acoramidis for ATTR-CM and Phase 3 candidates for Achondroplasia, ADH1, and LGMD2I.
BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon
BridgeBio Pharma focuses on developing therapies for genetic diseases with a threefold approach to managing costs and timelines effectively. The company employs a threefold R&D strategy: streamlined discovery, decentralized teams, and efficient development processes. BBIO's pipeline includes late-stage drug candidates like Acoramidis for ATTR-CM and Phase 3 candidates for Achondroplasia, ADH1, and LGMD2I.